Australia's CSL slumps to near 7-year low on delaying vaccine division spinoff

Csl

27/10/2025 23:22

** Shares of CSL CSL.AX tanked as much as 16.6% to A$176.23, hitting their lowest level since December 24, 2018

** Stock set for weakest trading session since mid-August, if current trends hold

** Biotech giant no longer expects to complete the spinoff of its vaccine division in fiscal 2026

** Co cites heightened volatility in the U.S. influenza vaccine market

** Demerger is now expected to occur when market conditions support maximizing shareholder value — CSL

** Stock down 35.8% YTD, as of last close

(Reporting by Shivangi Lahiri in Bengaluru)

((shivangi.lahiri@thomsonreuters.com))